PharmGED: pharmacogenetic effect database.

Prediction and elucidation of pharmacogenetic effects is important for facilitating the development of personalized medicines. Knowledge of polymorphism-induced and other types of drug-response variations is needed for facilitating such studies. Although databases of pharmacogenetic knowledge, polymorphism and toxicogenomic information have appeared, some of the relevant data are provided in separate web-pages and in terms of relatively long descriptions quoted from literatures. To facilitate easy and quick assessment of the relevant information, it is helpful to develop databases that provide all of the information related to a pharmacogenetic effect in the same web-page and in brief descriptions. We developed a database, Pharmacogenetic Effect Database (PharmGED), for providing sequence, function, polymorphism, affected drugs and pharmacogenetic effects. PharmGED can be accessed at http://bidd.cz3.nus.edu.sg/phg/ free of charge for academic use. It currently contains 1825 entries covering 108 disease conditions, 266 distinct proteins, 693 polymorphisms, 414 drugs/ligands cited from 856 references.

[1]  H. McLeod,et al.  Will pharmacogenetics allow better prediction of methotrexate toxicity and efficacy in patients with rheumatoid arthritis? , 2003, Annals of the rheumatic diseases.

[2]  Klaus Lindpaintner,et al.  Pharmacogenetics and the future of medical practice. , 2002, Journal of molecular medicine.

[3]  M. Hiratsuka,et al.  Genotyping of the N-acetyltransferase2 polymorphism in the prediction of adverse drug reactions to isoniazid in Japanese patients. , 2002, Drug metabolism and pharmacokinetics.

[4]  M Masellis,et al.  A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: association with tardive dyskinesia in schizophrenia , 2000, Molecular Psychiatry.

[5]  W. Kalow.  Pharmacogenetics, pharmacogenomics, and pharmacobiology , 2001, Clinical pharmacology and therapeutics.

[6]  M. Relling,et al.  Moving towards individualized medicine with pharmacogenomics , 2004, Nature.

[7]  Russ B Altman,et al.  Challenges for biomedical informatics and pharmacogenomics. , 2002, Annual review of pharmacology and toxicology.

[8]  C. Nemeroff,et al.  Prediction of Antidepressant Response to Milnacipran by Norepinephrine Transporter Gene Polymorphisms , 2004 .

[9]  P. Nelemans,et al.  Influence of SERTPR and STin2 in the serotonin transporter gene on the effect of selective serotonin reuptake inhibitors in depression: a systematic review , 2004, Molecular Psychiatry.

[10]  Alan Dove,et al.  Proteomics: translating genomics into products? , 1999, Nature Biotechnology.

[11]  Hiten Vyas,et al.  An information-driven approach to pharmacogenomics. , 2005, Pharmacogenomics.

[12]  Xin Chen,et al.  Internet resources for proteins associated with drug therapeutic effects, adverse reactions and ADME. , 2003, Drug discovery today.

[13]  Russ B. Altman,et al.  A call for the creation of personalized medicine databases , 2006, Nature Reviews Drug Discovery.

[14]  A. Marshall.  Laying the foundations for personalized medicines , 1998, Nature Biotechnology.

[15]  A. Marshall.  Getting the right drug into the right patient , 1998, Nature Biotechnology.

[16]  Giorgio Palù,et al.  Comparative evaluation of three computerized algorithms for prediction of antiretroviral susceptibility from HIV type 1 genotype. , 2004, The Journal of antimicrobial chemotherapy.

[17]  G. Hochhaus,et al.  Methods used to assess pulmonary deposition and absorption of drugs. , 2001, Drug discovery today.

[18]  M. Relling,et al.  Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  A. Beresford,et al.  ADME/PK as part of a rational approach to drug discovery. , 2000, Drug discovery today.

[20]  S. Kasper,et al.  Genetic polymorphisms for drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia , 1998, Schizophrenia Research.

[21]  N. Meropol,et al.  UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[22]  Yusuke Nakamura,et al.  Japanese single nucleotide polymorphism database for 267 possible drug‐related genes , 2006, Cancer science.

[23]  A. Roses,et al.  Pharmacogenetics to Predict Drug-Related Adverse Events , 2004, Toxicologic pathology.

[24]  G. Stormo,et al.  PolyMAPr: Programs for polymorphism database mining, annotation, and functional analysis , 2005, Human Mutation.

[25]  A. Li,et al.  Screening for human ADME/Tox drug properties in drug discovery. , 2001, Drug discovery today.

[26]  Joshua M. Stuart,et al.  Integrating genotype and phenotype information: an overview of the PharmGKB project , 2001, The Pharmacogenomics Journal.

[27]  C. J. Zheng,et al.  Drug ADME‐associated protein database as a resource for facilitating pharmacogenomics research , 2004 .

[28]  N. Thuerauf,et al.  CYP2D6 Genotype: Impact on Adverse Effects and Nonresponse During Treatment with Antidepressants—a Pilot Study , 2004, Clinical pharmacology and therapeutics.

[29]  A. Y. Lu,et al.  Role of pharmacokinetics and metabolism in drug discovery and development. , 1997, Pharmacological reviews.

[30]  C. Debouck,et al.  The impact of genomics on drug discovery. , 2000, Annual review of pharmacology and toxicology.

[31]  S Scharpé,et al.  Peptide truncation by dipeptidyl peptidase IV: a new pathway for drug discovery? , 2001, Verhandelingen - Koninklijke Academie voor Geneeskunde van Belgie.

[32]  S. Spector,et al.  An MDR1-3435 variant is associated with higher plasma nelfinavir levels and more rapid virologic response in HIV-1 infected children , 2005, AIDS.

[33]  N. Ozawa,et al.  Transporter Database, TP-Search: A Web-Accessible Comprehensive Database for Research in Pharmacokinetics of Drugs , 2004, Pharmaceutical Research.

[34]  Thierry Buclin,et al.  Polymorphisms in Human MDR1 (P‐glycoprotein): Recent Advances and Clinical Relevance , 2004, Clinical pharmacology and therapeutics.

[35]  Yu Zong Chen,et al.  Drug Adverse Reaction Target Database (DART) , 2003, Drug safety.

[36]  X. Chen,et al.  TTD: Therapeutic Target Database , 2002, Nucleic Acids Res..

[37]  A. Salter,et al.  Large-scale databases in toxicogenomics. , 2005, Pharmacogenomics.

[38]  H. Nicholls.  Improving drug response with pharmacogenomics. , 2003, Drug discovery today.

[39]  D. Goldstein,et al.  Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. , 2003, The New England journal of medicine.

[40]  J. Ordovás,et al.  Interactions between common genetic polymorphisms in ABCG5/G8 and CYP7A1 on LDL cholesterol-lowering response to atorvastatin. , 2004, Atherosclerosis.

[41]  T. Lehtimäki,et al.  Interaction between NOTCH4 and catechol-O-methyltransferase genotypes in schizophrenia patients with poor response to typical neuroleptics. , 2004, Pharmacogenetics.

[42]  Xin Chen,et al.  ADME-AP: a database of ADME associated proteins , 2002, Bioinform..

[43]  C. Cusin,et al.  Influence of tryptophan hydroxylase and serotonin transporter genes on fluvoxamine antidepressant activity , 2001, Molecular Psychiatry.